A BSTRACT During perfusion with a glucose concentration of 150 mg/100 ml, infusions of L-epinephrine, L-norepinephrine, and D-L-isoproterenol at physiological concentrations of 2 ng/ml for 9 min stimulated secretion of glucagon in a monophasic response pattern, in contrast to the biphasic response normally encountered after glucagon releasing stimuli as previously reported from our laboratory (1971. J. Clin. Invest. 50: 2123). Glucagon was stimulated in spite of a glucose concentration which in itself effectively inhibits glucagon release. Release of insulin was strongly inhibited after epinephrine and norepinephrine, and strongly stimulated after isoproterenol.
INTRODUCTION
Infusions of epinephrine (1) and norepinephrine (2) will inhibit release of insulin in man. This inhibition of insulin release has also been demonstrated in studies on pancreatic slices (3), in isolated islets (4) , and recently in the isolated perfused rat pancreas (5) . The use of specific alpha and beta receptor blockers have clearly indicated that the inhibition of insulin release is an alpha receptor effect while stimulation of insulin release by adrenergic substances is mediated through beta receptors (6, 7) .
Thus far it is not known whether secretion of pancreatic glucagon is influenced by adrenergic substances and whether the alpha cells of the islets of Langerhans possess adrenergic receptors as has been shown for the beta cells. The purpose of the present study was to investigate the effect of epinephrine, norepinephrine, and isoproterenol upon the secretion of glucagon and insulin in the isolated perfused canine pancreas and by use of specific receptor blocking compounds to elucidate the receptors responsible.
METHODS
Fasting male mongrels weighing 20-30 kg were anesthetized with thiopentone, intubated, and ventilated with positive pressure respiration, using 02 and NO, in ratio of 1: 3.
The operative procedure was carried out and the perfusion system established as described in detail in a previous publication (8) . The preparation consisted of the pancreas and the proximal 10 cm of the attached duodenum. Corp., Raritan, N. J., and fumarate, pyruvate, and glutamate each at a concentration of 5 mM. Glucose concentration of the perfusate was 25 mg/100 ml. The perfusate was equilibrated by a roller screen oxygenator in an atmosphere of 94.4%702 and 5.6% CO2 and was heated to a temperature of 37±1°VC by use of low wattage heaters with a large surface area. The perfusate was pumped through the gland by m-eans of a roller pump. A constant flow rate of 18-20 ml/min was achieved with a perfusion pressure which settles between 30 and 40 mm Hg within 5-10 minutes after start of the perfusion. Flow and pressure were constant throughout the experiment. Biochemical methods. Glucagon and insulin were measured by radioimmunoassay using minor modifications of the wick chromatography method described by 0rskov (9, 10) . (For details see 11.) In order to decrease the sensitivity limit for exact determinations of the low insulin values obtained during perfusion with a glucose concentration of 25 mg/100 ml sample size was increased from 20 IAI to 85 F1. 2 min before and during infusion of the catecholamines and the blocking substances the hormone concentrations were measured in duplicate determinations. The hormone concentrations in the rest of the experiments were measured in single determinations.
In the glucagon assay it is possible to distinguish differences in glucagon concentrations of 10 pg/ml with 95% confidence (O pg/ml standards, N = 6, vs. 10 pg/ml standards, n = 3). The antiglucagon serum employed does not distinguish between glucagon-like activity from the gut and glucagon from the pancreas. However, the present preparation consists of the pancreas and only the proximal 10 cm of the attached duodenum which contains very little or no glucagon-like immunoreactivity (12) (13) (14) .
No proteolytic enzymes escaped from the perfused pancreas. This was apparent from the fact that incubation damage to hormones in the perfusate was identical to that calculated from the standard media both as estimated chromatographically by the nonspecific migration of labeled hormone with plasma proteins and immunologically as the maximum binding of labeled hormone in the presence of an antibody excess.
Glucose was measured using a glucose oxidase method (Glox, Kabi Reagents, Stockholm, Sweden). There was no interference from the high dextran concentrations.
Experimental procedure. Samples were taken every minuate from the influx and the efflux. Influx samples were checked at intervals for the correct glucose concentration. To protect glucagon against degradation 250 ,ul EDTA (30%o) was added to the tubes collecting the efflux, resulting in a final concentration of 4 mg/ml. The samples were transferred within a half hour to a freezer providing a temperature of -20°C.
The substances to be examined were added to the perfusate by means of constant infusion syringes, containing appropriate high concentrations. The infusion pumps were adjusted to speeds which added 0.1-0.25 ml/min to the overall flow which was 18-20 ml/min. When any of the substances was administered it was dissolved immediately before use in purified distilled water adjusted to a pH of 3.5.
L-epinephrine and L-norepinephrine (Sigma Chemical Co., St. Louis, Mo.), isoproterenol (obtained as DL-N-isopropylarterenol), propanolol (Inderal, Ayerst Laboratories, New York), phentolamine (Regitine, Ciba Pharmaceutical Co., Summit. N. J.) and dibenzyline (obtained as phenoxybenzamine HCI) were commercially available. The standard curves for glucagon and insulin were not effected by the adrenergic substances or the receptor blocking compounds.
The pancreas was perfused for an equilibration period of 20-30 min with a glucose concentration of 25 mg/100 ml. The glucagon and insulin response to glucose concentrations of 25, 150, and 350 mg/100 ml was investigated. The effect of adrenergic substances was investigated at glucose concentrations of 25 mg/100 ml and 150 mg/100 ml in the perfusate.
Two different experimental set ups were chosen for investigating the effect of adrenergic substances. In the first (type I experiment) the effect of several agents was tested in the same pancreas. Although it was found that the effect of the different catecholamines was of a short duration, lasting only until termination of the infusion, care was taken to reverse the order of stimulations in the different experiments to ensure that the response seen after one stimulus was not influenced by the previous one. The effect of the receptor blockers, propanolol and phentolamine, was investigated by comparing the effect of the catecholamine alone with the effect of a simultaneous infusion of the blocker and the same catecholamine.
When one of the receptor blocking compounds had been infused, subsequent testing of the pancreas always consisted of a simultaneous infusion of-the same receptor blocker and an adrenergic substance, as preliminary experiments had shown that stimulation subsequent to infusion of blockers was influenced by the continued effect of the blocker. This suggested that elimination of these compounds from the tissue was slow. For the same reason the effects of an alpha receptor blocker and a beta receptor blocker were never investigated in the same perfusion experiment.
In the second experimental procedure (type II experiment) the effect of only one catecholamine was investigated in each experiment. The blocker was either infused over a period of 10 min prior to the catecholamine infusion or the catecholamine infusion-preceded that of the blocker by 10-15 min. The results from these two experimental sereis (type I and type II experiments) were comparable.
At the end of each experiment the insulin response to a glucose concentration of 350 mg/ml was checked in order to prove that the beta cells were still capable of the characteristic biphasic insulin response.
RESULTS
Effect of epinephrine, norepinephrine, and isoproterenol during perfusion with glucose concentrations of 25 and 150 mg/100 ml (type I experiments) Stimulation of glucagon secretion was obtained in all of 23 perfusion experiments with an infusion of epinephrine (2 ng/ml for 9 min), in each of 8 perfusion experiments with an infusion of norepinephrine (2 ng/ml for 9 min) and in each of 11 perfusion experiments with an infusion of isoproterenol (2 ng/mI for 9 min).
The different pancreatic preparations under the same standardized conditions showed a variability in their tern previously reported following gastrin, pancreozyThe stimulatory effect of the adrenergic substances min, and arginine stimulation (11) . Glucagon rose was studied at low glucose concentrations as well as at within 1 or 2 min to a plateau which was almost con-the high concentration of glucose of 150 mg/100 ml, stant until termination of the infusion upon which the which effectively inhibits basal glucagon secretion in glucagon concentration gradually leveled off to the pre-our experiments. At See footnotes Table I. lated secretion of glucagon almost to the same degree. and following isoproterenol it rose to 138% (SEM Following epinephrine the glucagon level increased to ±+19, N = 5) ( 3). During perfusion with a glucose concentration of the characteristic response pattern seen after an incre-150 mg/100 ml epinephrine increased glucagon to 165% ment in glucose, gastrointestinal hormones, and amino (SEM ±27, N = 18) (Fig. 1) . Norepinephrine in-acids. The mean insulin level rose to a peak at 2 min of creased glucagon to 81% (SEM ±38, N = 6) ( rine at a glucose concentration of 25 mg/100 ml the mean glucagon level was -2% (SEM +1, N 3) (Fig. 1) ; after propanolol and norepinephrine it was 3% (N =2) (Fig. 2) and after propanolol and isoproterenol it was 1% (N=2) (Fig. 3) . During perfusion with a glucose concentration of 150 mg/100 ml propanolol also abolished or suppressed the catecholinduced glucagon release. After propanolol and epinephrine glucagon was 11% (SEM±6, N=4) (Fig. 2) .
After propanolol and isoproterenol the glucagon release was completely abolished in three experiments and suppressed to a smaller extent in one experiment. The glucagon level during the infusion was 36% (SEM ±29, N = 4). Excluding the experiment where the less pronounced suppression was obtained the mean percentage was 6% (SEM ±8, N=3) (Fig. 3) .
Infusion of propanolol and epinephrine and propanolol and norepinephrine tended to accentuate the inhibition of insulin release induced by these substances alone at a glucose concentration of 150 mg/100 ml. Furthermore the transient stimulatory effect of epinephrine upon insulin release was completely abolished, the 2 min insulin value being -4% (SEM ±6). After propanolol and epinephrine insulin decreased to a mean level during the last 6 min of the infusion of -68% (SEM -+4, N = 10) (Fig. 1) . After propanolol and norepinephrine it decreased to -55% (SEM ±4, N = 4) (Fig. 2) . Infusion of propanolol and isoproterenol induced a smaller insulin release than that obtained after isoproterenol alone. However, propanolol was not able to abolish the response completely. Insulin rose to a peak at 2 min of 238% (N = 2) and leveled off to a plateau at about the prestimulation value, namely 9% (Fig. 3) . During perfusion with a glucose concentration of 25 mg/100 ml propanolol and epinephrine caused a slight decrease in insulin to -29% (SEM ±9, N = 3) (Fig. 3) during the infusion. Propanolol and norepinephrine did not alter insulin release at this glucose concentration. Propanolol and isoproterenol completely abolished the increase in insulin seen after isoproterenol alone, insulin during the infusion being 3% (N = 2) with no spike at 2 min (Fig. 3) .
Phentolamine. Phentolamine (1 /uM) and epinephrine tended to cause an enhanced release of glucagon in comparison to the release seen after epinephrine alone. During perfusion with low glucose concentrations glucagon rose to 66% (N = 2) (Fig. 1) . Phentolamine caused no change in the glucagon release when infused together with norepinephrine in one experiment as compared with an infusion of norepinephrine alone. Glucagon rose to 42%. Simultaneous infusion of phentolamine and isoproterenol also caused no further increase in glucagon compared to the increase seen after isoproterenol alone. It rose to 142% (N = 2) (Fig. 3) . , and isoproterenol and phentolamine infusion *-0 in the different perfusion experiments both at a glucose concentration of 150 mg/100 ml (left) and at 25 mg/100 ml (right). Table III gives the corresponding mean concentrations (±+SEM) from the same experiments and the number of stimulations.
During perfusion with high glucose concentrations phentolamine also appeared not to influence the catechol-induced glucagon release. After phentolamine and epinephrine glucagon rose to 94% (SEM +29, N = 5) (Fig. 1) , after phentolamine and norepinephrine it rose to 50% (N = 2) (Fig. 2) and after phentolamine and isoproterenol the value was 170% (N = 2) (Fig. 3) .
At a glucose concentration of 150 mg/100 ml infusion of phentolamine together with epinephrine or norepinephrine reversed the inhibition of insulin release obtained with these substances alone. The insulin release now followed a biphasic release pattern as described following isoproterenol. After phentolamine and epinephrine insulin rose to 777% (SEM 197, N = 5) at 2 min and leveled off at a plateau of 420% (SEM ±84) (Fig. 1) . After phentolamine and norepinephrine it increased to 100% (N = 2) at 2 min followed by a plateau of 41% (Fig. 2) . The addition of phentolamine to an isoproterenol infusion induced no change in insulin release. The same biphasic pattern was obtained as after isoproterenol alone. Insulin rose to 1,615% (N = 2) and leveled off at a plateau of 1,039% (Fig. 3 ).
I -a
At the low glucose concentration alpha receptor blockade abolished the slight decrease in insulin seen after epinephrine alone and did not affect the response seen after norepinephrine. After isoproterenol in two experiments there was an increase to 136% during the infusion (Fig. 3) . The 2 min value was not different from the mean value during the entire infusion.
Effect of dibenzyline upon epinephrineinfluenced release and effect of propanolol upon isoproterenol-and epinephrine-influenced release during perfusion with a glucose concentration of 150 mg/100 ml (type II experiments) Dibenzyline. As the presence of alpha receptors on glucagon producing cells in the pancreas could not be clearly demonstrated using the alpha blocking compound pherntolamine, it was decided to try another alpha blocker, dibenzyline, which, having slightly different pharmacological characteristics, might have advantages over phentolamine. Furthermore the effect of only one catecholamine was investigated in each experiment to avoid possible errors that might be inherent in the experimerntal situations where several agents were tested in the same perfusion experiment.
The glucagon response to a 15 min infusion of epinephrine was compared to a 15 min infusion of epinephrine and dibenzyline, which was preceded by a 10 min infusion of dibenzyline alone. Three such experiments were performed at 150 mg/100 ml glucose. Using this experimental design, dibenzyline in one experiment enhanced the catechol-induced glucagon release (Fig. 4) ; in two other experiments a slight suppression was seen. The effect of dibenzyline upon the catecholinfluenced insulin release was unambiguous: it caused a reversal of the epinephrine-induced inhibition to a stimulation.
In another series of four experiments dibenzyline was infused 10-15 min after start of the epinephrine infusion in order to study whether an alpha receptor blockade during catechol-induced glucagon release would change the pattern of release. Again no consistent change in glucagon release was observed. In two experiments there was a slight though insignificant enhancement of the glucagon release (Fig. 5) ; in two other experiments no effect was obtained (Fig. 6) VI and Fig. 7 ). In one experiment (Fig. 8) propanolol was infused 10 min after start of an epinephrine infusion. Again glucagon was suppressed and insulin release further inhibited. The figure also shows an identical biphasic glucagon response to arginine before and after the blocker infusion proving intact responsiveness of the alpha cells during the experimental period. DISCUSSION In the present investigation results are reported on the effect of adrenergic substances on the secretion of pancreatic glucagon and insulin. The study has shown that epinephrine, norepinephrine, and isoproterenol stimulate secretion of glucagon. Furthermore the stimulatory effect of these substances has been characterized to be mediated through beta receptors. New observations and confirmatory evidence on the effect of adrenergic substances on the secretion of insulin has also been presented.
In vivo studies on the effect of adrenergic substances on the secretion of glucagon have not been reported. The results from studies on the isolated incubated pancreatic tissue have been contradictory. Vance, Buchanan, and Williams (15) In the present in vitro study epinephrine and norepinephrine in concentrations as low as 2 ng/ml-i.e., within the levels occurring during exercise, stress, and hypoglycemia-stimulated release of glucagon during perfusion with a glucose concentration of 150 mg/100 ml which in itself blocks the basal glucagon release. A significant effect was also obtained with catecholamine concentrations as low as 0.5 ng/ml (results not shown).
The catechols investigated all stimulated glucagon in a monophasic response pattern different from the characteristic biphasic release of glucagon following infusions of pancreozymin, gastrin, and arginine preAdrenergic Receptors and the Secretion of Glucagon and Insulin E 190.7±-3.3 (9) 352.2±-11.5 (9) 368.0±-7.0 (15) 374.0-±7.1 (10) I 268.8±-4.3 (6) 982 82.2±-5.3 (7) 623 2,159.6±t98.0 (13) 1,553.6±-77.6 (9) 3 PG 277.0--12.2 (10) 784.7±t20.6 (14) 830.2±-35.1 (15) 951.3±-31. (12) 3 PG 65.8±-3.3 (12) 225.7±t4.8 (14) 76.9±t1.8 (12) 190.3±t3.5 (13) 1 269.3±-4.7 (6) 618 94.7±t2.5 (12) 244.8±t9.5 (12) 2,545
824.3±469.1 (12) See footnotes Table I and: J § Number of samples obtained duriing the prestimulation period and during infusioni of epinephrine, epinephrine and dibenzyline, and epinephrine.
111 The mean insulin concentrationi (±SEM) durinig the infusioni minius the first three samples.
viously reported from our laboratory (11) . An attractive explanation for this difference in response could be that the adrenergic stimulation of the alpha cells influenced alpha and beta receptors to a varying degree, the response observed, being a net result of stimulatory and inhibitory effects upon the release and not a one- See footnotes Table I. way stimulatory effect as exerted by gastrointestinal hormones and amino acids (however, see later). The beta receptor stimulant (17) , isoproterenol, was a potent releaser of glucagon. Furthermore our finding that isoproterenol-induced glucagon release was suppressed or completely abolished by simultaneous infusion of the specific beta receptor blocking compound, propanolol, has clearly demonstrated that the mechanism responsible for glucagon release following adrenergic substances was via a beta receptor.
On the basis of preliminary experiments we reported results that indicated that epinephrine induced a slightly higher glucagon release during alpha receptor blockade than the release attained after epinephrine alone (18) . Closer analysis, however, revealed that this augmented release was insignificant. Epinephrine also did not suppress glucagon release below the preinfusion level during simultaneous infusion of propanolol. These two findings might indicate that no alpha receptors were present on the alpha cells of the islets of Langerhans or so few that they might be considered to have no importance. However, the negative results could also be due to pitfalls in the experimental design: (a) The presence of a catecholamine during the development of blockade by a halyalkylamine might cause a competition between the two drugs for the same population of receptors (19, 20) . (b) The concentration of the blocking compounds used might be insufficient to produce a total receptor blockade on the alpha cell even if it appeared to be effective on the beta cell. (c) A catecholamine infusion might influence the functional state of the alpha cells in such a way that a later simultaneous catecholamine-alpha-blocker infusion would not be able to produce a higher increment. (d) The fact that several agents were often tested in the same perfusion experiment (type I experiments) might influence the responses obtained.
We tried to avoid these possible pitfalls, using another design and using high doses of dibenzyline, another alpha receptor blocking compound, which is more readily bound to the tissue and more potent. In one experimental series dibenzyline was infused 10 min prior to the catecholamine infusion to ensure saturation of the alpha receptors before introducing epinephrine into the system. In another series of experiments dibenzyline was given 10 min after start of the catecholamine infusion during the first hour of the perfusion period to make it less likely that a lack of effect was due to an altered functional activity of the alpha cell or to an exhausted alpha cell population. In both instances alpha-blockade by dibenzyline did not consistently enhance epinephrine induced glucagon release, while release of insulin was influenced as expected, exhibiting a stimulation instead of an inhibition. When the betaadrenergic blocking agent propanolol was investigated using the same experimental design (type II experiments) isoproterenol-and epinephrine-induced glucagon release was greatly suppressed and insulin release suppressed or further inhibited. The fact that a nonadrenergic substance like the amino acid arginine at physiological concentrations releases glucagon to the same degree before and after a catecholamine and blocker infusion speaks for an intact responsiveness of the alpha cell. Thus on the basis of the present experimental preparation and set-up, we may conclude that no evidence could be obtained supporting the presence of alpha receptors on the alpha cells of the islets of Langerhans.
Epinephrine and norepinephrine inhibited secretion of insulin, while isoproterenol was a strong stimulus for theory is the recent in vivo observation that propanolol suppresses tolbutamide-induced insulin release (21) . In this connection it nmay also be of interest that our results have shown that isoproterenol releases insulin at a glucose concentration normally found insufficient for many insulin releasing stimuli. Isoproterenol, in this respect, thus appears to resemble substances like tolbutamide and leucine. Whether this means that isoproterenol, tolbutamide, and leucine share a common receptor, or fit better into one part of a receptor which enables them to release insulin, is only speculative at the moment. (Fig. 9) . Our results are thus consistent with most in vitro and in vivo data concerning the effect of catechols on insulin release. Our demonstration that epinephrine has a short transient stimulatory effect upon insulin release before inhibition takes place, and that this effect is completely abolished during beta blockade has not been described previously.
It is interesting that the insulin responses to epinephrine and norepinephrine during simultaneous alpha blockade of the organ always followed a biphasic release pattern similar to that seen after glucose, gastrointestinal hormones, amino acids, tolbutamide, and the beta receptor stimulant isoproterenol. This might lead us to suggest that the effect of these physiological stim- It has been suggested by Porte (22) that the catecholamine release which is stimulated by infection, stress, and volume depletion may be an important factor in some patients with diabetic ketoacidosis increasing glycogenolysis and lipolysis and inhibiting insulin release. It would appear from the foregoing that pancreatic glucagon secreted in response to increased catechol levels would fit in with this theory and contribute to a worsening of the situation by augmenting glycogenolysis and gluconeogenesis in the liver.
Bottger, Faloona, and Unger reported a rise in pancreatic glucagon after heavy exercise in fasting dogs (23 
